According to reports this morning in the diabetes news, the European Union has now given approval to diabetes drug Eucreas. Novartis, a Swiss pharmaceutical company, submitted the drug for approval and were successful.
The drug, Eucreas, combined Galvus (a recently approved DPP-4 inhibitor) with metformin. The drug is to treat diabetics by increasing insulin sensitivity. Manufacturer Novartis reportedly commented: “The approval comes after Novartis proposed changes to the EU label recommending that liver monitoring should be conducted.”
Once the European Medicines Agency has approved a drug, which they did to Eucreas in September, approval usually follows amongst all 27 nations. Galvus, a potential blockbuster diabetes drug for Novartis, has been found to cause liver problems amongst some diabetic patients.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…